A nurse in a health clinic is assisting in the care of a client diagnosed with chlamydia. The client was prescribed azithromycin 1 g PO once. Which of the following allergy findings in the client's history should the nurse report to the provider?

Choice A reason: Diminished pulses signal compromised circulation, a critical cast complication like compartment syndrome. This risks tissue necrosis or amputation if untreated, prioritizing it scientifically, as arterial flow disruption demands immediate intervention to preserve limb viability per vascular assessment standards.

Choice B reason: Ecchymosis suggests bruising, possibly from cast pressure, but isn’t immediately life-threatening like poor circulation. It’s a secondary concern, manageable later. Scientifically, it indicates trauma, not acute vascular emergency, ranking lower in urgency per cast complication protocols.

Choice C reason: Muscle spasms may indicate irritation or pressure, but they’re less urgent than absent pulses. Pain is common in casts, not always critical. Scientifically, this suggests nerve or muscle stress, not imminent tissue loss, making it a lower priority for immediate action.

Choice D reason: One fingerbreadth space is normal, preventing tightness, not a concern. It’s ideal fit, not a problem. Scientifically, this aligns with safe cast application, lacking urgency compared to circulatory threats, as it supports, rather than jeopardizes, limb health.

Choice A reason: Every 2 hours for wheezing is incorrect; montelukast is daily, not PRN. Scientifically, it’s a leukotriene inhibitor for prevention, not acute relief, showing misunderstanding of its chronic asthma management role versus rescue inhalers.

Choice B reason: Once daily in the evening is correct for montelukast, optimizing its anti-inflammatory effect overnight. Scientifically, this aligns with pharmacokinetics and asthma’s nocturnal worsening, indicating accurate understanding of its administration for long-term control.

Choice C reason: Stopping with steroids is wrong; montelukast complements, not replaces, them. Scientifically, it targets different pathways (leukotrienes vs. corticosteroids), and combined use enhances control, reflecting a misgrasp of its additive role in asthma therapy.

Choice D reason: Two months for efficacy is false; montelukast acts within days. Scientifically, its leukotriene blockade reduces inflammation quickly, not over months, suggesting misunderstanding of its rapid onset in asthma symptom prevention per evidence.